Amphotericin B and micafungin duo-loaded nanoemulsion as a potential strategy against Candida auris biofilms.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI:10.1080/08927014.2024.2396020

Gabriel Davi Marena, André Luiz Carneiro Soares do Nascimento, Gabriela Corrêa Carvalho, Rafael Miguel Sábio, Tais Maria Bauab, Marlus Chorilli

{"title":"Amphotericin B and micafungin duo-loaded nanoemulsion as a potential strategy against Candida auris biofilms.","authors":"Gabriel Davi Marena, André Luiz Carneiro Soares do Nascimento, Gabriela Corrêa Carvalho, Rafael Miguel Sábio, Tais Maria Bauab, Marlus Chorilli","doi":"10.1080/08927014.2024.2396020","DOIUrl":null,"url":null,"abstract":"Candida auris is a multidrug-resistant yeast that has seen a worrying increase during the COVID-19 pandemic. Give7/n this, new therapeutic options, such as controlled-release nanomaterials, may be promising in combating the infection. Therefore, this study aimed to develop amphotericin B (AmB) and micafungin (MICA)-loaded nanoemulsions (NEMA) and evaluated against biofilms of C. auris. Nanoemulsions (NEs) were characterized and determined minimum inhibitory concentration MIC90, checkerboard and anti-biofilm. NEMA presented a size of 53.7 and 81.4 nm for DLS and NTA, respectively, with good stability and spherical morphology. MICAmB incorporated efficiency was 88.4 and 99.3%, respectively. The release results show that AmB and MICA obtained a release of 100 and 63.4%, respectively. MICAmB and NEMA showed MIC90 values of 0.015 and 0.031 ug/mL, respectively and synergism. NEMA showed greater metabolic inhibition and morphological changes in mature biofilms. This drugs combination and co-encapsulation proved to be a promising therapy against C. auris biofilms.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/08927014.2024.2396020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Candida auris is a multidrug-resistant yeast that has seen a worrying increase during the COVID-19 pandemic. Give7/n this, new therapeutic options, such as controlled-release nanomaterials, may be promising in combating the infection. Therefore, this study aimed to develop amphotericin B (AmB) and micafungin (MICA)-loaded nanoemulsions (NEMA) and evaluated against biofilms of C. auris. Nanoemulsions (NEs) were characterized and determined minimum inhibitory concentration MIC₉₀, checkerboard and anti-biofilm. NEMA presented a size of 53.7 and 81.4 nm for DLS and NTA, respectively, with good stability and spherical morphology. MICAmB incorporated efficiency was 88.4 and 99.3%, respectively. The release results show that AmB and MICA obtained a release of 100 and 63.4%, respectively. MICAmB and NEMA showed MIC90 values of 0.015 and 0.031 ug/mL, respectively and synergism. NEMA showed greater metabolic inhibition and morphological changes in mature biofilms. This drugs combination and co-encapsulation proved to be a promising therapy against C. auris biofilms.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

两性霉素 B 和米卡芬净双载纳米乳液作为一种潜在的抗念珠菌生物膜策略。

白色念珠菌是一种对多种药物产生抗药性的酵母菌，在 COVID-19 大流行期间，这种酵母菌的数量出现了令人担忧的增长。因此，新的治疗方案（如控释纳米材料）在抗感染方面可能大有可为。因此，本研究旨在开发负载两性霉素 B（AmB）和米卡芬净（MICA）的纳米乳剂（NEMA），并评估其对阴道杆菌生物膜的作用。对纳米乳剂（NEs）进行了表征，并确定了最低抑菌浓度 MIC90、棋盘格和抗生物膜。纳米乳剂的 DLS 和 NTA 尺寸分别为 53.7 纳米和 81.4 纳米，具有良好的稳定性和球形形态。MICAmB 的掺入效率分别为 88.4% 和 99.3%。释放结果表明，AmB 和 MICA 的释放率分别为 100%和 63.4%。MICAmB 和 NEMA 的 MIC90 值分别为 0.015 微克/毫升和 0.031 微克/毫升，具有协同作用。NEMA 对成熟生物膜的代谢抑制和形态变化更大。事实证明，这种药物组合和共包囊是一种很有前景的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊